Doximity (DOCS)
Health Care · Digital Health / Professional Networks · NYSE
Doximity is the leading digital professional network for U.S. physicians, connecting them with each other and offering AI-powered productivity tools while providing healthcare enterprises with targeted marketing and recruitment solutions.
What Doximity does
Doximity is a digital platform and professional network specifically for U.S. physicians and other medical professionals, offering tools to streamline clinical workflows, career management, and patient communication. The company monetizes its large user base through marketing, hiring, and workflow solutions sold to pharmaceutical manufacturers and health systems. Its platform leverages data science and AI-powered tools to facilitate medical networking, news delivery, and telehealth services.
Themes: digital health, AI in healthcare / ambient documentation, physician productivity, telehealth, healthcare marketing / advertising, digital recruiting / medical staffing, healthcare SaaS
Fundamentals
- Price$33.35 as of 2026-10-20 close
- Market cap$6.0B as of 2026-06-30 (share count; price 2026-10-20)
- 1-year return-51.0% 2025-10-20 close $68.00 → 2026-10-20 close $33.35
- P/E39.70 as of 2026-10-20
- Net margin+30.4% FY2026, SEC XBRL
- Gross margin+89.1% FY2026, SEC XBRL
- ROE+20.6% FY2026, SEC XBRL
- ROICn/a No figure: its filing tags none of the debt lines we read, which is not evidence of zero debt.
- Debt / equityn/a No figure: its filing tags none of the debt lines we read, which is not evidence of zero debt.
- Revenue growth (YoY)+13.1% FY2026, SEC XBRL
- Revenue CAGR (3y)+15.5% SEC XBRL
- Beta1.04 as of 2026-09-03
- Last reported earnings2026-08-06 SEC EDGAR Form 8-K (Item 2.02)
How DOCS compares in its sector
- price-to-earnings ratiomiddle range 181 covered Health Care peers, as of 2026-10-20
- net profit margintop 10% 430 covered Health Care peers, as of 2026-09-03
- operating margintop 10% 417 covered Health Care peers, as of 2026-09-03
- gross margintop 10% 189 covered Health Care peers, as of 2026-09-03
- return on equitytop 25% 510 covered Health Care peers, as of 2026-09-03
- 3-year revenue CAGRmiddle range 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)top 25% 494 covered Health Care peers, as of FY2026
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
DOCS is not currently in any published Top 10 list. Its scores are below.
Top 10 score
63.0 #135 of 1,265 scored · #18 of 146 in Health Care
Financial health 97th (free cash flow margin 50.6%) and profitability 83rd (operating margin 33.3%, return on equity 20.6%); weakest is valuation (27th, price to book 6.5, price to earnings 39.7).
Scores as of 20 Oct 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 4.
Quarterly results
| Quarter | Revenue | Gross profit | Operating income | Net income | Diluted EPS | Operating cash flow | Capex |
|---|---|---|---|---|---|---|---|
| Q1 FY2027 2026-06-30 | $157M | $133M | $34M | $24M | $0.13 | $42M | $62000 |
| Q4 FY2026 2026-03-31 | $145M† | $126M† | $25M† | $19M† | $0.10† | $110M† | — |
| Q3 FY2026 2025-12-31 | $185M | $166M | $72M | $62M | $0.31 | $61M† | — |
| Q2 FY2026 2025-09-30 | $169M | $152M | $64M | $62M | $0.31 | $94M† | — |
| Q1 FY2026 2025-06-30 | $146M | $130M | $55M | $53M | $0.27 | $62M | $0 |
| Q4 FY2025 2025-03-31 | $138M† | $124M† | $49M† | $62M† | $0.31† | $98M† | $0† |
| Q3 FY2025 2024-12-31 | $169M | $154M | $80M | $75M | $0.37 | $65M† | $0† |
| Q2 FY2025 2024-09-30 | $137M | $123M | $53M | $44M | $0.22 | $68M† | $0† |
† Not filed as a discrete quarter: derived from the company's own year-to-date figures (for example the fourth quarter as the fiscal year minus the first nine months). A derived per-share figure is approximate, because the share count moves within the year.
Balance sheet at 2026-06-30
- Cash and equivalents$274M
- Total debtnot shown the filing tags none of the debt lines we read — not evidence of zero debt
From the company's own SEC 10-Q and 10-K filings (XBRL), re-read every week. Figures in US dollars as filed; informational only — not financial advice.
How Doximity looks technically
Doximity (DOCS) is trading 25.7% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 3 trading days ago — a "golden cross", a bullish long-term signal. A strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 42, with buyers in control. Momentum is stretched — its 14-day RSI (a 0–100 momentum gauge) is 74, in overbought territory (above 70). It just made a new 20-day high, its first since 2026-02-04, pushing above its recent trading range. It is 53.3% below its highest point of the past year.
Trend
9
| Distance from the 200-day | it is trading 25.7% above its 200-day average, the long-term trend line — a longer-term uptrend | +25.7% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $27.01 | $27.01 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $26.54 | $26.54 |
| Swing structure | each recent peak has been higher than the one before it and each dip has been shallower — the pattern chart-watchers call an uptrend, which describes where price has already been and not where it goes next | higher highs and higher lows |
| Last swing turn | its last significant turn was a swing low 22 calendar days ago — the swings before that are what the structure reading is measured on | 22 sessions |
| Wave structure | its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five; the labelling fails if price closes below 25.33. It is one of several labellings that fit, and it describes the swings already printed, not what comes next. The same swings also read as a three-part correction in leg C. | possible upward five-wave sequence, in wave 3 (one of several readings) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 3 trading days ago — a "golden cross", a bullish long-term signal | 3 sessions |
| Above the 200-day after a dip | it recently dipped to its 200-day average (the long-term trend line) and has since climbed back above it — now about 25.7% above | +25.7% |
| Trend strength (14-day ADX) | a strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 42, with buyers in control | 42.0 |
Momentum
3
| 14-day RSI | momentum is stretched — its 14-day RSI (a 0–100 momentum gauge) is 74, in overbought territory (above 70) | 73.9 |
|---|---|---|
| Position in its 14-day range | it is trading near the top of its 14-day range ($27.52 to $34.10) — its "stochastic" reading is 89 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 88.6 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in positive territory (momentum leaning bullish) | 15 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $71.37 | $71.37 |
|---|---|---|
| From the 52-week high | it is 53.3% below its 52-week high (its highest price of the past year) | -53.3% |
| Above the 52-week low | it is 94.5% above its 52-week low (its lowest price of the past year) | +94.5% |
| Below the 52-week high | it is 53.3% below its highest point of the past year | 53.3% |
| Since a 20-day breakout | it just made a new 20-day high, its first since 2026-02-04, pushing above its recent trading range | 1 session |
| Since a 55-day breakout | it just made a new 55-day high, its first since 2026-02-04, pushing above its recent trading range | 1 session |
| All-time high | its highest closing price on record is $107.79 (set on 2021-09-10) | $107.79 |
| Given back of the 52-week move | over the past year its closes ranged ($18.01 to $68.50), and it has recovered roughly a third of its fall from last year’s high — 30% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $49.21 to $50.83. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 30.4% |
| From the all-time high | it is 69.1% below its all-time high | -69.1% |
| Nearest price level | it is trading 17.8% above a support level at $27.40 — a price it turned at twice since 2026-09-03, most recently on 2026-09-22. Since 2024-10-21 it has 7 such levels below the current price and 10 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -17.8% |
| All-time low | its lowest closing price on record is $17.15 (set on 2026-05-14) | $17.15 |
| Above the all-time low | it is 94.5% above its all-time low | +94.5% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are wider than usual versus its own recent 6-month history (wider than about 73% of it) | 73rd percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $1.34 between its high and its low — about 4.0% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $1.34 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $24.84 and $33.03 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $24.84 – $28.94 – $33.03 |
| Typical daily range (% of price) | its price moves about 4.0% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 4.0% |
| Stretch from the 200-day average | it is trading 5.1 daily ranges above its 200-day average price (25.7% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 5.1 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 1.40× |
|---|
Analyst
2
| Change in the average price target | analysts have raised their average price target by 2.6% since the prior reading | +2.6% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
2
| Since a doji | 6 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 6 sessions ago |
|---|---|---|
| Since a bullish engulfing | 3 sessions ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 3 sessions ago |
Price gaps
3
| Gap at the open | it opened on 2026-10-20 1.6% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and had not traded back through that level by the close | +1.6% |
|---|---|---|
| Open gap | it gapped 88.1% above the previous close 51 sessions ago and has not traded back through the level it left behind at 20.66 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +88.1% |
| Gap filled | a 2.0% gap up opened on 2026-10-01 has been "filled" 13 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 13 sessions ago |
Price streaks
1
| Closing streak | it has closed higher 2 sessions in a row, a +7.68% move over the run — an unbroken run of up days, which describes what has already happened and says nothing about the next session | 2 sessions up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 26.8 percentage points (the stock gained 27.7% while the market gained 1.0%) | +26.8% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 49.8 percentage points (the stock gained 53.5% while the market gained 3.6%) | +49.8% |
| vs market, 6 months | over the past 6 months this stock beat the market by 28.2 percentage points (the stock gained 36.7% while the market gained 8.5%) | +28.2% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 65.5 percentage points (the stock lost 51.0% while the market gained 14.6%) | -65.5% |
Signal agreement
2
| Bullish technical signals | 7 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, a fresh 20-day high, MACD momentum is positive, a strong uptrend, with buyers in control, outperforming the market over 6 months, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 7 of 9 |
|---|---|---|
| Bearish technical signals | 2 of the 9 technical signals we can compute for it are currently in a bearish state: its RSI momentum gauge is overbought (a stretched reading), near the top of its 14-day range (overbought) — these describe past price behaviour, not a forecast | 2 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 11% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-14 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is moderate, spanning 3.4% of the share price. | +11.4% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 30% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $25.67 — a volume-weighted average of daily closes over 196 sessions, not a true tick-by-tick VWAP. | +29.9% |
|---|---|---|
| Vs the average paid since it last reported | the price is 26% above the average price paid since it last reported on 2026-08-06 (its 10-Q), so the typical buyer over that stretch is showing a gain. That average is $26.53 — a volume-weighted average of daily closes over 53 sessions, not a true tick-by-tick VWAP. | +25.7% |
Price levels it has turned at before
DOCS last closed at $33.35 on 2026-10-20. Since 2024-10-21 it has turned at 7 prices below its last close and 10 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $27.40 | Support | 17.8% below the last close | turned there twice · 2026-09-03 to 2026-09-22 |
| $26.89 | Support | 19.4% below the last close | turned there twice · 2026-03-05 to 2026-05-12 |
| $25.46 | Support | 23.6% below the last close | turned there three times · 2026-03-23 to 2026-09-28 |
| $43.23 | Resistance | 29.6% above the last close | turned there twice · 2025-12-23 to 2026-01-02 |
| $46.48 | Resistance | 39.4% above the last close | turned there three times · 2025-11-20 to 2026-01-06 |
| $48.00 | Resistance | 43.9% above the last close | turned there three times · 2024-11-21 to 2025-05-16 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five.
This labelling fails — stops being a possible reading at all — if it closes below $25.33.
This is one of several labellings that fit the same swings, so treat it as a reading rather than the reading. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
On past moves of this shape the leg has usually ended somewhere between $28.86 and $31.03 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
Alternate reading: The same swings also read as a three-part correction in leg C, which fails on a close below $25.33.
This reading has stood for 11 trading days, since 2026-10-06.
Read from daily closes as of 2026-10-20.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Trading above the 50-day moving average · Recent golden cross (50-day crossed above 200-day) · Tested and reclaimed 200-day support · Overbought (14-day RSI above 70) · Pulled back from the 12-month high | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low
Based on daily closing prices as of 2026-10-20. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingHold (2.62 mean, 1=Strong Buy…5=Strong Sell) — 18 analysts
- Mean price target$30.44 range $18.00 – $47.00; median $29.00
Analyst estimates, as of 2026-10-15. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for DOCS
- Consensus EPS estimate$0.3508 next reporting period, as of 2026-10-15
- Estimate change, 30 days+$0.00114 (+0.3%) from $0.3496, on 2026-09-10, 35-day window
- Readings revised upward11% of 9 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Reliance on a relatively small number of large pharmaceutical and health system customers for a significant portion of revenue.","Ability to maintain and grow platform engagement amidst rapid technological changes in AI and digital health.","Exposure to risks related to data privacy, cybersecurity, and evolving healthcare regulatory requirements."]
What changed in the latest 10-Q
AI-assisted comparison of DOCS's 10-Q filed 2026-08-06 against the prior one filed 2026-02-05.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing states Doximity has over 3 million registered members as of March 31, 2026, with a footnote defining a registered member as a user who completed the registration flow by claiming a pre-populated profile or creating a new profile.
- Newer filing states that as of March 31, 2026, the total number of U.S. physicians was approximately 1 million and provides the criteria used to calculate U.S. physicians.
- Newer filing describes the company's AI-powered tools and Clinical AI Suite, including Ask (formerly DoxGPT) and Scribe, supporting physician workflow from patient communication to documentation to answering clinical questions.
- Newer filing includes quarterly unique active providers using Workflow Tools as a key business and financial metric, with a definition that includes Ask, PeerCheck, Amion scheduling, and Scribe as qualifying workflow functions.
- Newer filing reports quarterly unique active providers using workflow tools increased approximately 32% year-over-year compared to June 30, 2025.
- Removed:
- Older filing includes a Non-GAAP Financial Measures section describing adjusted EBITDA and free cash flow, including definitions and limitations.
- Older filing reports results for the three and nine months ended December 31, 2025 and 2024, including revenue, net income, and adjusted EBITDA figures that are not in the newer filing.
- Reworded:
- Newer filing references the Annual Report on Form 10-K filed with the SEC on May 19, 2026, while the older filing references May 20, 2025.
- Newer filing describes the current fiscal year as Fiscal 2027 ending March 31, 2027, while the older filing describes Fiscal 2026 ending March 31, 2026.
- Newer filing describes the company as 'the leading digital platform for U.S. medical professionals, with over 3 million registered members as of March 31, 2026,' whereas the older filing describes it as 'the leading digital platform for U.S. medical professionals, as measured by the number of members.'
- Newer filing changes 'physicians-first' to 'physician-first' and changes 'Doximity puts modern software in the hands of physicians and other medical professionals' to a description of AI-powered tools built for medicine.
- Newer filing reports revenue of $156.6 million and $145.9 million for the three months ended June 30, 2026 and 2025 (7% growth), net income of $24.3 million and $53.3 million, and adjusted EBITDA of $74.8 million and $79.8 million; the older filing reports different figures for the three and nine months ended December 31, 2025 and 2024.
- Newer filing reports 127 customers with at least $500,000 of TTM revenue as of June 30, 2026 compared to 119 as of June 30, 2025, and states this cohort accounted for approximately 83% of revenue for the TTM ended June 30, 2026; the older filing reports 126 customers as of December 31, 2025 compared to 115 as of December 31, 2024, accounting for approximately 84% of revenue for the TTM ended December 31, 2025.
- Newer filing reports a net revenue retention rate of 107% as of June 30, 2026 compared to 118% as of June 30, 2025; the older filing reports 112% as of December 31, 2025 compared to 117% as of December 31, 2024.
- Newer filing includes additional narrative before the net revenue retention rate definition describing the metric's purpose, while the older filing places the definition before the comparative description.
- Newer filing's customer metric heading reads 'Customers with Trailing 12-Month Subscription Revenue Greater than $500,000' and states the metric is 'a key indicator of the scale of our business and the value we create for large customers'; the older filing heading omits 'Subscription' and states the metric is 'a key indicator of the scale of our business.'
- Notes:
- The newer filing text was truncated mid-sentence in the provided excerpt at the discussion of quarterly unique active providers, so some content in the newer MD&A may not have been fully compared.
- The older filing provided only a partial MD&A excerpt, and its Non-GAAP Financial Measures section may extend beyond the provided text; removal of that section is based only on the provided excerpt.
Risk Factors
- Added:
- Newer filing (2026-08-06) states there have been no material changes to the risk factors in the Annual Report on Form 10-K for the fiscal year ended March 31, 2026.
- Newer filing (2026-08-06) refers to the Annual Report on Form 10-K for the fiscal year ended March 31, 2026.
- Newer filing (2026-08-06) Section Item 5 includes trading plan activity for Anna Bryson, Phoebe Yang, and Kira Wampler.
- Removed:
- Older filing (2026-02-05) included risk factor heading 'We may become subject to litigation, which could have a material adverse effect on our business, financial condition, and results of operations.' with accompanying paragraph.
- Older filing (2026-02-05) included risk factor heading 'We may seek to grow our business through acquisitions of, or investments in, new or complementary businesses, technologies, tools, or solutions, or through strategic alliances, and the failure to manage these acquisitions, investments or alliances, or to integrate them with our existing business, could have a material adverse effect on us.' with accompanying paragraphs.
- Older filing (2026-02-05) Item 5 disclosed that no directors or executive officers adopted, modified or terminated a Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement during the quarter except Phoebe Yang's plan.
- Reworded:
- Older filing (2026-02-05) referred to the Annual Report on Form 10-K for the fiscal year ended March 31, 2025; newer filing (2026-08-06) refers to the Annual Report on Form 10-K for the fiscal year ended March 31, 2026.
- Older filing (2026-02-05) stated 'Other than the risk factors set forth below, there have been no material changes from the risk factors discussed in our Annual Report' and then listed two risk factors; newer filing (2026-08-06) states 'There have been no material changes to the risk factors included in our Annual Report' without listing any risk factors.
- Older filing (2026-02-05) Risk Factors section contained substantive risk factor text; newer filing (2026-08-06) Risk Factors section contains only a statement that there were no material changes.
- Notes:
- The provided newer Risk Factors excerpt includes subsequent Form 10-Q sections (Items 2-6 and signatures) beyond the Risk Factors section, while the provided older excerpt also includes subsequent sections; the comparison focuses on the Risk Factors section content.
- The older and newer filing excerpts for Risk Factors differ in structure because the older filing included the full text of two risk factors while the newer filing contains only a cross-reference statement.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 8 open-market sales by insiders in the last 90 days, of which we have read Form 4 filings through 2026-10-16. The 5 days since 2026-10-16 have not been checked yet.
- Last 30 days · read to 2026-10-160 buys · 3 sells ($172443) — 3 selling insiders
- Last 90 days · read to 2026-10-160 buys · 8 sells ($666515) — 4 selling insiders
- Last 180 days · read to 2026-10-160 buys · 12 sells ($1M) — 4 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-10-14. Based on Form 4 filings read through 2026-10-16; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about DOCS's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
U.S. House trading disclosures
U.S. House members publicly disclose their own, their spouse's, and dependent children's stock transactions under the STOCK Act. We hold 2 matched disclosures for DOCS from U.S. House Clerk Periodic Transaction Report filings.
U.S. House trading disclosures →Institutional ownership (13F)
6 institutional 13F filers reported holding DOCS as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 6
- Reported shares held 26,017,137
- Reported value $539,595,430
reported quarterly holdings change (2026-03-31 → 2026-06-30): 0 new, 4 increased, 2 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about DOCS's institutional holders → See what each manager we track holds →
Short interest (FINRA)
DOCS had 11,284,181 shares of reported short interest as of the 2026-09-30 FINRA settlement date (delayed, bi-monthly; not real-time).
DOCS had 6.27% of its shares outstanding sold short as of the 2026-09-30 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 3.55 days to cover at the same settlement.
- Reported short interest (shares) 11,284,181
- Short interest (% of shares outstanding) 6.27%
- Prior settlement (shares) 12,382,007
- Reported change -8.87%
- Days to cover (reported) 3.55
Reported to FINRA as of the 2026-09-30 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- LinkedIn (MSFT)
- WebMD (KKR)
- Medscape (KKR)
- Sermo
- Epic Systems
- Teladoc Health (TDOC)
- Amwell (AMWL)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare DOCS vs…
Doximity is found in…
DOCS ranks in…
Frequently asked questions
What does Doximity (DOCS) do?
Doximity is a digital platform and professional network specifically for U.S. physicians and other medical professionals, offering tools to streamline clinical workflows, career management, and patient communication. The company monetizes its large user base through marketing, hiring, and workflow solutions sold to pharmaceutical manufacturers and health systems. Its platform leverages data science and AI-powered tools to facilitate medical networking, news delivery, and telehealth services.
What sector is Doximity (DOCS) in?
Doximity (DOCS) is classified in the Health Care sector. Its industry is Digital Health / Professional Networks. It trades on NYSE.
Who are Doximity's (DOCS) competitors?
Notable peers of Doximity (DOCS) include LinkedIn, WebMD, Medscape, Sermo and Epic Systems. This peer set is informational only — not financial advice.
Has there been recent U.S. House stock trading in DOCS?
Yes — we hold 2 matched STOCK Act disclosures for DOCS from U.S. House Clerk Periodic Transaction Report filings. These are legally-required disclosures (often filed 30–45 days after the trade), may belong to a U.S. House member, their spouse, or a dependent child, and are not an indicator of company performance or investment advice.
Is Doximity (DOCS) overbought or oversold right now?
Doximity (DOCS) is currently in overbought territory (its 14-day RSI is 74, above 70) (as of 2026-10-20). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on DOCS come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest; prices are market data, as of 2026-09-03; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-20.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.